Journals / Dicle Tıp Dergisi / 2020 / Cilt: 47 Sayı: 1

The Relationship Between MicroRNAs And Congenital Kidney Anomalies

Kenan Yılmaz(SELÇUK ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, PATOLOJİ (DR) (ERCİYES ÜNİV. ORTAK))
Zubeyde Gunduz(BİTLİS EREN ÜNİVERSİTESİ, SOSYAL BİLİMLER ENSTİTÜSÜ, TARİH (DR) (ERCİYES ÜNİV. ORTAK))
Mehmet Serdar Kutuk(ERCİYES ÜNİVERSİTESİ, KAYSERİ ATATÜRK SAĞLIK YÜKSEKOKULU)
Ruhan Dusunsel(ERCİYES ÜNİVERSİTESİ, KAYSERİ MESLEK YÜKSEKOKULU)
İsmail Dursun(ERCİYES ÜNİVERSİTESİ, KAYSERİ MESLEK YÜKSEKOKULU)
Sibel Yel(ERCİYES ÜNİVERSİTESİ, KAYSERİ MESLEK YÜKSEKOKULU)
Pages
89–96
Publication Date
2020-03-17
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, this miRNA may be used in the antenatal early detection of these congenital kidney anomalies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to identify diagnostic microRNAs (miRNAs) associated with congenital kidney anomalies.
📊
Key Findings & Data:Serum samples were taken from the pregnant women at the moment of diagnosis in the antenatal 20th gestational week, whereas serum samples were taken from the cord blood of babies during birth.
💡
Conclusion & Impact:Thus, this miRNA may be used in the antenatal early detection of these congenital kidney anomalies.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:microRNAs · kidney development · biomarker

Özet

Objective: The purpose of this study was to identify diagnostic microRNAs (miRNAs) associated with congenital kidney anomalies. Methods: Twenty-five healthy pregnant women who were found to have fetal kidney anomaly in the second trimester of their pregnancy at Department of Perinatology, were included in the study. Serum samples were taken from the pregnant women at the moment of diagnosis in the antenatal 20th gestational week, whereas serum samples were taken from the cord blood of babies during birth. There were 11 multicystic dysplastic kidney patients, 6 autosomal recessive polycystic kidney patients, and 8 unilateral hypoplastic kidney patients. Expression of specific miRNAs was monitored using specific primer assays in Real-Time PCR. The expression of the following miRNAs was quantified: miR-17, miR-192, miR-194, miR-204, miR-215, and miR-216. Results: mir-17 expression was significantly lower in children with congenital kidney anomalies than in the control group. ROC curve analysis showed that the area under the curve was 0.700 for miR-17 in the prediction of congenital kidney anomalies. Conclusions: In children with congenital kidney anomalies, miR-17 expression was significantly different than in the control group. Thus, this miRNA may be used in the antenatal early detection of these congenital kidney anomalies.

🔖

Cite This Article

Yılmaz, K., Gunduz, Z., Kutuk, M. S., Dusunsel, R., Dursun, İ., Yel, S. (2020). The Relationship Between MicroRNAs And Congenital Kidney Anomalies. Dicle Tıp Dergisi, Cilt: 47 Sayı: 1, 89–96. https://doi.org/10.5798/dicletip.706048

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Vivante A, Kohl S, Hwang DY, Dworschak GC, Hildebrandt F. Single-genecauses of congenital anomalies of the kidney and urinary tract (CAKUT) in humans. PediatrNephrol. 2014; 29: 695-704.
  2. Ho J, Kreidberg JA. MicroRNAs in renal development. PediatrNephrol. 2013; 28: 219-25.
  3. Dias T, Sairam S, Kumarasiri S. Ultrasound diagnosis of fetal renal abnormalities. Best Pract Res ClinObstetGynaecol. 2014; 28: 403-15.
  4. van de Hoek G, Nicolaou N, Giles RH, Knoers NV, Renkema KY, Bongers EM. Functional models for congenital anomalies of the kidney and urinary tract. Nephron. 2015; 129: 62-7.
  5. dos Santos Junior AC, de Miranda DM, Simões e Silva AC. Congenital anomalies of the kidney and urinary tract: an embryogenetic review. Birth Defects Res C Embryo Today. 2014; 102: 374-81.
  6. Caruana G, Bertram JF. Congenital anomalies of the kidney and urinary tract genetics in mice and men. Nephrology (Carlton). 2015; 20: 309-11.
  7. Baldassarre A, Felli C, Prantera G, Masotti A. Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases. Genes (Basel). 2017; 8: 234.
  8. Makarova JA, Shkurnikov MU, Turchinovich AA, Tonevitsky AG, Grigoriev AI. Circulating microRNAs. Biochemistry (Mosc). 2015; 80: 1117-26.
  9. Ivey KN, Srivastava D. microRNAs as Developmental Regulators. Cold Spring HarbPerspect Biol. 2015; 7: a008144.
  10. Van der Hauwaert C, Savary G, Hennino MF, Pottier N, Glowacki F, Cauffiez C. MicroRNAs in kidney fibrosis. NephrolTher. 2015; 11: 474-82.
  11. Kito N, Endo K, Ikesue M, Weng H, Iwai N. miRNA Profiles of Tubular Cells: Diagnosis of Kidney Injury. Biomed Res Int. 2015; 2015: 465479.
  12. Akkina S, Becker BN. MicroRNAs in kidney function and disease. Transl Res. 2011; 157: 236-40.
  13. Badal SS, Danesh FR. MicroRNAs and their applications in kidney diseases. PediatrNephrol. 2015; 30: 727-40.
  14. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015; 11: 23-33.
  15. Bhatt K, Kato M, Natarajan R. Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2016; 310: 109-18.
  16. Ho J, Pandey P, Schatton T, et al. The pro-apoptotic protein Bim is a MicroRNA target in kidney progenitors. J Am SocNephrol. 2011; 22: 1053–63.
  17. Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon AP, Yu J. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int. 2011; 79: 317-30.
  18. Zhao H, Ma SX, Shang YQ, Zhang HQ, Su W. micro RNAs in chronic kidney disease. ClinChimActa. 2019; 491: 59-65.
  19. Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014; 134: 833-45.
  20. Pandey P, Brors B, Srivastava PK, et al. Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics. 2008; 9: 624.
  21. Sun H, Li QW, Lv XY, et al. MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. MolBiol Rep. 2010; 37: 2951–8.
  22. Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest. 2008; 118: 3714–24.
  23. Ho J, Pandey P, Schatton T, et al. The pro-apoptotic protein Bim is a MicroRNA target in kidney progenitors. J Am SocNephrol. 2011; 22: 1053–63.
  24. Zhu S, Cao L, Zhu J, et al. Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. ClinChimActa. 2013; 424: 66-72.
  25. Song Y, Higgins H, Guo J, et al. Clinical significance of circulating microRNAs as markers in detecting and predicting congenital heart defects in children. J Transl Med. 2018; 2: 42.
  26. Wojciechowska A, Braniewska A, Kozar-Kamińska K. MicroRNA in cardiovascular biology and disease. AdvClinExp Med. 2017; 26: 865-74.
  27. Weber DG, Casjens S, Rozynek P, et al. Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks. Biomark Insights. 2010; 5: 95-102.